Question 1

Which countries lead Eosinophilic Esophagitis research?

Accepted Answer

By volume, the United States and China publish the most (1.9k and 586 works in 2022-now).

Question 2

Which institutions lead Eosinophilic Esophagitis research?

Accepted Answer

By volume in 2022-now, University of North Carolina at Chapel Hill publishes the most Eosinophilic Esophagitis research, followed by Mayo Clinic and Harvard University.

Question 3

Who are the leading researchers in Eosinophilic Esophagitis?

Accepted Answer

The most-cited researchers publishing on Eosinophilic Esophagitis include George Davey Smith, Walter Churchill Willett and Mark J. Daly.

Question 4

Where is Eosinophilic Esophagitis research done?

Accepted Answer

The largest centres of Eosinophilic Esophagitis research in 2022-now are New York (United States), London (United Kingdom), Tokyo (Japan) and Beijing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Cincinnati and Scottsdale.

Question 5

Where is the best place to study Eosinophilic Esophagitis?

Accepted Answer

Among universities, judged by research, McMaster University, University of Cincinnati and Humanitas University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is Eosinophilic Esophagitis research growing?

Accepted Answer

Output in 2022-2025 was 9% higher than in 2018-2021, peaking in 2024. The fastest-growing topics are Eosinophilic Esophagitis.

Question 7

What are the most cited papers in Eosinophilic Esophagitis?

Accepted Answer

The most cited paper in Eosinophilic Esophagitis is "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease" (Yasunori Ogura, Denise K. Bonen, Naohiro Inohara et al., 2001), with 5,051 citations. Next come "IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines" (3,763) and "Global strategy for asthma management and prevention: GINA executive summary" (3,258).